Literature DB >> 3913529

Albumin microspheres as drug carriers.

Y Morimoto, S Fujimoto.   

Abstract

In order to improve the therapeutic index in cancer chemotherapy, it is necessary to deliver antitumor agents to target sites (tumor sites). One of the methods used to deliver those agents to target sites is to employ nontoxic and biodegradable drug carriers. Considerable efforts have been directed toward the development of drug carriers, i.e., DNA complexes, protein-drug conjugates, lactic/glycolic acid polymer, liposomes, emulsion, etc. Albumin microsphere is one of those drug carriers. This review describes the progress which has been made during the last 10 to 15 years in the application of albumin microspheres as drug carriers to cancer chemotherapy. It will cover a wide range of subjects including the preparation and physicochemical properties of microspheres containing antitumor agents, pharmacokinetics of the microspheres in experimental animals, and the antitumor efficacy by intra-arterial use against human primary metastatic liver tumor.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3913529

Source DB:  PubMed          Journal:  Crit Rev Ther Drug Carrier Syst        ISSN: 0743-4863            Impact factor:   4.889


  3 in total

Review 1.  Optimisation of treatment by applying programmable rate-controlled drug delivery technology.

Authors:  Yie W Chien; Senshang Lin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Biodistributions of air-filled albumin microspheres in rats and pigs.

Authors:  P Walday; H Tolleshaug; T Gjøen; G M Kindberg; T Berg; T Skotland; E Holtz
Journal:  Biochem J       Date:  1994-04-15       Impact factor: 3.857

3.  Production of recombinant albumin by a herd of cloned transgenic cattle.

Authors:  Yann Echelard; Jennifer L Williams; Margaret M Destrempes; Julie A Koster; Susan A Overton; Daniel P Pollock; Karen T Rapiejko; Esmail Behboodi; Nicholas C Masiello; William G Gavin; Jerry Pommer; Scott M Van Patten; David C Faber; Jose B Cibelli; Harry M Meade
Journal:  Transgenic Res       Date:  2008-11-22       Impact factor: 2.788

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.